Cargando…

Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions

Objective: To evaluate the safety and efficacy of the Phil liquid embolic agent in non-neurological embolization procedures. M&M: Thirty-five patients with a mean age of 62.5 years underwent percutaneous embolization using Phil for the treatment of visceral arterial bleedings in 20/35 patients (...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucatelli, Pierleone, Corona, Mario, Teodoli, Leonardo, Nardis, Piergiorgio, Cannavale, Alessandro, Rocco, Bianca, Trobiani, Claudio, Cipollari, Stefano, Zilahi de Gyurgyokai, Simone, Bezzi, Mario, Catalano, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916888/
https://www.ncbi.nlm.nih.gov/pubmed/33670124
http://dx.doi.org/10.3390/jcm10040701
_version_ 1783657580407554048
author Lucatelli, Pierleone
Corona, Mario
Teodoli, Leonardo
Nardis, Piergiorgio
Cannavale, Alessandro
Rocco, Bianca
Trobiani, Claudio
Cipollari, Stefano
Zilahi de Gyurgyokai, Simone
Bezzi, Mario
Catalano, Carlo
author_facet Lucatelli, Pierleone
Corona, Mario
Teodoli, Leonardo
Nardis, Piergiorgio
Cannavale, Alessandro
Rocco, Bianca
Trobiani, Claudio
Cipollari, Stefano
Zilahi de Gyurgyokai, Simone
Bezzi, Mario
Catalano, Carlo
author_sort Lucatelli, Pierleone
collection PubMed
description Objective: To evaluate the safety and efficacy of the Phil liquid embolic agent in non-neurological embolization procedures. M&M: Thirty-five patients with a mean age of 62.5 years underwent percutaneous embolization using Phil for the treatment of visceral arterial bleedings in 20/35 patients (including three gluteal, one bladder, two superior mesenteric, three epigastric, one deep femoral, five internal iliac, four intercostal, and one lingual arteries), splanchnic pseudoaneurysms in 11/35 patients (including three hepatic, five splenic, and three renal arteries), pancreatic bleeding metastasis in 1/35 patient, and gastric bleeding varices in 3/35 patients. Phil is composed of a non-adhesive copolymer dissolved in DMSO (Anhydrous Dimethyl Sulfoxide) with different viscosity. Procedures were performed slowly under continuous fluoroscopic guidance to avoid embolization of non-target vessels. Results: Clinical success was obtained with a single intervention in 34 cases (97.15%), while a repeated procedure was required in one case (2.85%). No technical complications nor non-target embolization occurred. A case of post-embolic syndrome was noted (2.85%) in one patient. DMSO administration-related pain was successfully controlled by medical therapy. Conclusion: Phil can be considered a safe and effective embolic agent for the treatment of non-neurologic bleeding.
format Online
Article
Text
id pubmed-7916888
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79168882021-03-01 Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions Lucatelli, Pierleone Corona, Mario Teodoli, Leonardo Nardis, Piergiorgio Cannavale, Alessandro Rocco, Bianca Trobiani, Claudio Cipollari, Stefano Zilahi de Gyurgyokai, Simone Bezzi, Mario Catalano, Carlo J Clin Med Article Objective: To evaluate the safety and efficacy of the Phil liquid embolic agent in non-neurological embolization procedures. M&M: Thirty-five patients with a mean age of 62.5 years underwent percutaneous embolization using Phil for the treatment of visceral arterial bleedings in 20/35 patients (including three gluteal, one bladder, two superior mesenteric, three epigastric, one deep femoral, five internal iliac, four intercostal, and one lingual arteries), splanchnic pseudoaneurysms in 11/35 patients (including three hepatic, five splenic, and three renal arteries), pancreatic bleeding metastasis in 1/35 patient, and gastric bleeding varices in 3/35 patients. Phil is composed of a non-adhesive copolymer dissolved in DMSO (Anhydrous Dimethyl Sulfoxide) with different viscosity. Procedures were performed slowly under continuous fluoroscopic guidance to avoid embolization of non-target vessels. Results: Clinical success was obtained with a single intervention in 34 cases (97.15%), while a repeated procedure was required in one case (2.85%). No technical complications nor non-target embolization occurred. A case of post-embolic syndrome was noted (2.85%) in one patient. DMSO administration-related pain was successfully controlled by medical therapy. Conclusion: Phil can be considered a safe and effective embolic agent for the treatment of non-neurologic bleeding. MDPI 2021-02-11 /pmc/articles/PMC7916888/ /pubmed/33670124 http://dx.doi.org/10.3390/jcm10040701 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lucatelli, Pierleone
Corona, Mario
Teodoli, Leonardo
Nardis, Piergiorgio
Cannavale, Alessandro
Rocco, Bianca
Trobiani, Claudio
Cipollari, Stefano
Zilahi de Gyurgyokai, Simone
Bezzi, Mario
Catalano, Carlo
Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions
title Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions
title_full Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions
title_fullStr Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions
title_full_unstemmed Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions
title_short Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions
title_sort use of phil embolic agent for bleeding in non-neurological interventions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916888/
https://www.ncbi.nlm.nih.gov/pubmed/33670124
http://dx.doi.org/10.3390/jcm10040701
work_keys_str_mv AT lucatellipierleone useofphilembolicagentforbleedinginnonneurologicalinterventions
AT coronamario useofphilembolicagentforbleedinginnonneurologicalinterventions
AT teodolileonardo useofphilembolicagentforbleedinginnonneurologicalinterventions
AT nardispiergiorgio useofphilembolicagentforbleedinginnonneurologicalinterventions
AT cannavalealessandro useofphilembolicagentforbleedinginnonneurologicalinterventions
AT roccobianca useofphilembolicagentforbleedinginnonneurologicalinterventions
AT trobianiclaudio useofphilembolicagentforbleedinginnonneurologicalinterventions
AT cipollaristefano useofphilembolicagentforbleedinginnonneurologicalinterventions
AT zilahidegyurgyokaisimone useofphilembolicagentforbleedinginnonneurologicalinterventions
AT bezzimario useofphilembolicagentforbleedinginnonneurologicalinterventions
AT catalanocarlo useofphilembolicagentforbleedinginnonneurologicalinterventions